Presentation is loading. Please wait.

Presentation is loading. Please wait.

Mechanisms of Acquired Resistance to AZD9291

Published byLaurel Pierce Modified over 5 years ago

Similar presentations

Presentation on theme: "Mechanisms of Acquired Resistance to AZD9291"— Presentation transcript:

1 Mechanisms of Acquired Resistance to AZD9291
Tae Min Kim, MD, Ahnah Song, MS, Dong-Wan Kim, MD, PhD, Soyeon Kim, PhD, Yong-Oon Ahn, PhD, Bhumsuk Keam, MD, Yoon Kyung Jeon, MD, Se-Hoon Lee, MD, Doo Hyun Chung, MD, Dae Seog Heo, MD  Journal of Thoracic Oncology  Volume 10, Issue 12, Pages (December 2015) DOI: /JTO Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Acquired resistance to AZD9291 in patient 1. A, Computed tomography of the chest showed a partial response to AZD9291 (middle; tumor reduction of 51.7% from baseline [left]) and progressive disease (right) (white arrow indicates mass in right upper lobe). B, Sanger sequencing of EGFR genes revealed the loss of EGFRT790M-mutant clones. C, The Integrated Genome Viewer revealed the depopulation of EGFRT790M-mutant clones in post-AZD9291 tumors. D, AZD9291-resistant tumors showed histologic transformation to small-cell carcinoma. Morphologically, poorly differentiated cells with a high nuclear-to-cytoplasmic ratio and neuroendocrine structure were observed in post-AZD9291 tumors (H&E, ×200). These were positive for CD56, chromogranin A, and synaptophysin by immunohistochemistry (×200). EGFR, epidermal growth factor receptor; H&E, hematoxylin and eosin. Journal of Thoracic Oncology  , DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Acquired resistance to AZD9291 in patient 2. A, Computed tomography of the chest showed a partial response to AZD9291 (middle; tumor reduction of 37.3% from baseline [left]) and progressive disease (right) (white arrow indicates soft tissue lesion in bone). Malignant pleural effusion decreased during response to AZD9291 but subsequently increased at progression. EGFRLREAT747del/T790M-mutant clones disappeared in post-AZD9291 tumors (B and C), and EGFR amplification remained present at disease progression (D). EGFR, epidermal growth factor receptor. Journal of Thoracic Oncology  , DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Acquired resistance to AZD9291 in patient 3. A, Computed tomography of the chest showed a partial response to AZD9291 (upper middle; tumor reduction of 49.2% from baseline [upper left]) and progressive disease (upper right) (white arrow indicates mass in right upper lobe). B and C, The loss of the EGFRT790M mutation was seen in post-AZD9291 tumors. D, AZD9291-resistant tumors showed focal FGFR1 amplification and high FGF2 mRNA expression as compared with baseline tumors. E, Relative mRNA expression levels of fibroblast growth factor receptor 1 (FGFR1) and basic fibroblast growth factor (FGF2) in HCC4006AR1-2 cells and parental HCC4006 cells were compared using quantitative PCR (qPCR). F, Cell proliferation assay of H1975 cells treated with 50 ng/ml FGF2 showed resistance to AZD9291. EGFR, epidermal growth factor receptor. Journal of Thoracic Oncology  , DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 Resistance to AZD9291 in patient 4 with focal progression and EGFRT790M-mutant NSCLC cells. A, Computed tomography of the chest showed a partial response to AZD9291 (lower middle and right; tumor reduction of 66.4% from the baseline [lower left]), but focal progression at right third rib (upper) (white arrows indicate soft tissue lesion in rib [upper] and mass in left lower lobe [lower]). B, EGF mRNA levels were increased in post-AZD9291 tumors, whereas EGFR gene copy number was not significantly increased in post-AZD9291 tumors as compared with pre-AZD9291 tumors. The hgDNA and HB-EGF denote human genome DNA and heparin-binding EGF-like growth factor, respectively. C, These were similar in AZD9291-resistant H1975 cells compared with parental H1975 cells. D, EGF supplementation conferred resistance to AZD9291 in H1975 cells. EGFR, epidermal growth factor receptor; NSCLC, non-small-cell lung cancer. Journal of Thoracic Oncology  , DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Mechanisms of Acquired Resistance to AZD9291"

Similar presentations

Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation 

Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation 
Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,
Neoplastic Fever Caused by Lung Cancer

Neoplastic Fever Caused by Lung Cancer
A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.
Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,

Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Next Generation Sequencing Uncovers Potential Genetic Driver Mutations of Malignant Pulmonary Granular Cell Tumor  Song Xu, Qingchun Zhao, Sen Wei, Yi.

Next Generation Sequencing Uncovers Potential Genetic Driver Mutations of Malignant Pulmonary Granular Cell Tumor  Song Xu, Qingchun Zhao, Sen Wei, Yi.
Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,

Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,
EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients  Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.

EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients  Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.
Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment  Jun Soo Ham, MD, Seokhwi Kim, MD, Hee Kyung.

Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment  Jun Soo Ham, MD, Seokhwi Kim, MD, Hee Kyung.
Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met–Amplified Adenocarcinoma of the.

Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met–Amplified Adenocarcinoma of the.
Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential Sensitivity 

Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential Sensitivity 
Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,
Characterization of Fibroblast Growth Factor Receptor 1 in Small-Cell Lung Cancer  Anish Thomas, MD, Jih-Hsiang Lee, MD, Zied Abdullaev, PhD, Kang-Seo.

Characterization of Fibroblast Growth Factor Receptor 1 in Small-Cell Lung Cancer  Anish Thomas, MD, Jih-Hsiang Lee, MD, Zied Abdullaev, PhD, Kang-Seo.
Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non–Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy  Sotirios Lakis,

Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non–Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy  Sotirios Lakis,
Clinicopathologic Analysis of ROS1-Rearranged Non–Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm  Heounjeong Go, MD, PhD, Dong-Wan Kim,

Clinicopathologic Analysis of ROS1-Rearranged Non–Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm  Heounjeong Go, MD, PhD, Dong-Wan Kim,
The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC  Si-Yang Liu, MD, Lan-Ying Gou, MD, An-Na Li, MD, Na-Na Lou, MMed, Hong-Fei.

The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC  Si-Yang Liu, MD, Lan-Ying Gou, MD, An-Na Li, MD, Na-Na Lou, MMed, Hong-Fei.
Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer  David R. Gandara, MD,

Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer  David R. Gandara, MD,
A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.

Similar presentations

Ads by Google